Compositions and methods for treating platelet storage pool deficiency, gray platelet syndrome and quebec platelet disorder
View Patent ↗The present invention relates to compositions and methods for treating diseases of coagulation using a NPP4 polypeptide.
1. A method of treating Platelet Storage Pool Deficiency in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated soluble NPP4 polypeptide comprising amino acid residues 1-407 of SEQ ID NO: 1.
2. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide is a recombinant NPP4 polypeptide.
3. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide lacks an NPP4 transmembrane domain.
4. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide consists of amino acid residues 1-407 of SEQ ID NO: 1.
5. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide is administered in combination with at least one other agent useful in treating bleeding.
6. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide is administered acutely or chronically.
7. The method of claim 1 , wherein the isolated soluble NPP4 polypeptide is administered locally, regionally or systemically.
8. The method of claim 1 , wherein the Platelet Storage Pool Deficiency is a Delta storage pool deficiency.
9. A method of treating Quebec Platelet disorder in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated soluble NPP4 polypeptide comprising amino acid residues 1-407 of SEQ ID NO: 1.
10. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide is a recombinant NPP4 polypeptide.
11. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide lacks an NPP4 transmembrane domain.
12. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide consists of amino acid residues 1-407 of SEQ ID NO: 1.
13. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide is administered in combination with at least one other agent useful in treating bleeding.
14. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide is administered acutely or chronically.
15. The method of claim 9 , wherein the isolated soluble NPP4 polypeptide is administered locally, regionally or systemically.
16. A method of treating Gray Platelet Syndrome in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated soluble NPP4 polypeptide comprising amino acid residues 1-407 of SEQ ID NO: 1.
17. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide is a recombinant NPP4 polypeptide.
18. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide lacks an NPP4 transmembrane domain.
19. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide consists of amino acid residues 1-407 of SEQ ID NO: 1.
20. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide is administered in combination with at least one other agent useful in treating bleeding.
21. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide is administered acutely or chronically.
22. The method of claim 16 , wherein the isolated soluble NPP4 polypeptide is administered locally, regionally or systemically.